Clinical Trial

Collection of Samples From the United States Population for Optimization and Evaluation of Colorectal Cancer (CRC) Plasma Circulating Free-DNA (cfDNA) Marker Panel Performance

Study acronym: PROVE
Recruiting
View on ClinicalTrials.gov →
Summary
This study is designed to prospectively collect blood samples and clinical data from patients that have been newly diagnosed with colorectal cancer and scheduled for resection surgery but are pre cancer treatment, subjects who are NOT scheduled for surgery but have histological confirmation of CRC from the diagnostic colonoscopy and clinical staging (cTMN) is available and are pr e- treatment, and patients who are at average risk of colorectal cancer and who are scheduled for routine colonoscopy examinations.
Trial Details
NCT Number NCT07310446
Lead Sponsor Universal Diagnostics
Conditions Colorectal Cancer
Enrollment 6,500 participants
Start Date 2023-07-31
Primary Completion 2026-12-31 (estimated)
Study Completion 2027-07 (estimated)
Updated on ClinicalTrials.gov 2025-12-30